Innovating Works

ORB

Desconocido
AUTOSTEM: Development of closed scalable and AUTOmated robotic systems for therapeutic STEM cell manufacturin... ORBSEN THERAPEUTICS LIMITED participó en un H2020: H2020-PHC-2014-2015 AUTOSTEM will develop closed, scaleable and automated systems for therapeutic cell manufacture. The project vision is a donor-to-patient sy...
2015-12-02 - 2018-12-31 | Financiado
BrainMatTrain: Development of Biomaterial based Delivery Systems for Parkinson s disease an Integrated Pan Europe... ORBSEN THERAPEUTICS LIMITED participó en un H2020: H2020-MSCA-ITN-2015 BrainMatTrain focuses on a comprehensive understanding of Parkinson’s disease (PD), from basics to translation, fully supported by 8 full pa...
2015-07-27 - 2019-12-31 | Financiado
NEPHSTROM: Novel Stromal Cell Therapy for Diabetic Kidney Disease ORBSEN THERAPEUTICS LIMITED participó en un H2020: H2020-PHC-2014-2015 Type 2 diabetes will affect >500 million adults by 2040 and its secondary complications will generate enormous socioeconomic costs - in part...
2015-04-08 - 2021-10-31 | Financiado
MERLIN: MEsenchymal stem cells to Reduce Liver INflammation ORBSEN THERAPEUTICS LIMITED participó en un FP7: Prevalence of liver disease is c6% (29 million people) in the EU with mortality rates from chronic liver diseases estimated at 14.3 per 100....
Financiado
VISICORT: Adverse Immune Signatures and their Prevention in Corneal Transplantation ORBSEN THERAPEUTICS LIMITED participó en un FP7: Immune system response is the most complex barrier to long-term success of tissue transplants/implants from allogeneic and bio-artificial so...
Financiado
PURSTEM: Utilisation of the mesenchymal stem cell receptome for rational development of uniform serum free c... ORBSEN THERAPEUTICS LIMITED participó en un FP7: Stem cells offer a promising avenue to therapy for a wide range of complaints. However, for this potential to be realized, a consistent and...
Financiado
DECIDE: Decision making within cells and differentiation entity therapies ORBSEN THERAPEUTICS LIMITED participó en un FP7: "Our ITN has both scientific and therapeutic targets. Research in Work Package 1 (WP1) aims to advance understanding of normal blood cell de...
Financiado
REDDSTAR: Repair of Diabetic Damage by Stromal Cell Administration ORBSEN THERAPEUTICS LIMITED participó en un FP7: 50 million diabetic EU citizens are using approved anti-diabetic agents to control their glycaemia. However, suboptimal glycemic control lea...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.